Literature DB >> 15125788

A meta-analysis of prior corticosteroid use and fracture risk.

John A Kanis1, Helena Johansson, Anders Oden, Olof Johnell, Chris de Laet, L Joseph Melton III, Alan Tenenhouse, Jonathan Reeve, Alan J Silman, Huibert A P Pols, John A Eisman, Eugene V McCloskey, Dan Mellstrom.   

Abstract

UNLABELLED: The relationship between use of corticosteroids and fracture risk was estimated in a meta-analysis of data from seven cohort studies of approximately 42,000 men and women. Current and past use of corticosteroids was an important predictor of fracture risk that was independent of prior fracture and BMD.
INTRODUCTION: The aims of this study were to validate that corticosteroid use is a significant risk factor for fracture in an international setting and to explore the effects of age and sex on this risk.
MATERIALS AND METHODS: We studied 42,500 men and women from seven prospectively studied cohorts followed for 176,000 patient-years. The cohorts comprised the EPOS/EVOS study, CaMos, the Rotterdam Study, Dubbo Osteoporosis Epidemiology Study (DOES), and prospective cohorts at Sheffield, Rochester, and Gothenburg. The effect of ever use of corticosteroids, BMD, age, and sex on all fracture, osteoporotic fracture, and hip fracture risk alone was examined using Poisson regression in each cohort and for each sex. The results of the different studies were merged from the weighted beta coefficients.
RESULTS: Previous corticosteroid use was associated with a significantly increased risk of any fracture, osteoporotic fracture, and hip fracture when adjusted for BMD. Relative risk of any fracture ranged from 1.98 at the age of 50 years to 1.66 at the age of 85 years. For osteoporotic fracture, the range of relative risk was 2.63-1.71, and for hip fracture 4.42-2.48. The estimate of relative risk was higher at younger ages, but not significantly so. No significant difference in risk was seen between men and women. The risk was marginally and not significantly upwardly adjusted when BMD was excluded from the model. The risk was independent of prior fracture. In the three cohorts that documented current corticosteroid use, BMD was significantly reduced at the femoral neck, but fracture risk was still only partly explained by BMD.
CONCLUSION: We conclude that prior and current exposure to corticosteroids confers an increased risk of fracture that is of substantial importance beyond that explained by the measurement of BMD. Its identification on an international basis validates the use of this risk factor in case-finding strategies. Copyright 2004 American Society for Bone and Mineral Research

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15125788     DOI: 10.1359/JBMR.040134

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  211 in total

Review 1.  Development and use of FRAX in osteoporosis.

Authors:  J A Kanis; E V McCloskey; H Johansson; A Oden; O Ström; F Borgström
Journal:  Osteoporos Int       Date:  2010-05-13       Impact factor: 4.507

2.  2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary.

Authors:  Alexandra Papaioannou; Suzanne Morin; Angela M Cheung; Stephanie Atkinson; Jacques P Brown; Sidney Feldman; David A Hanley; Anthony Hodsman; Sophie A Jamal; Stephanie M Kaiser; Brent Kvern; Kerry Siminoski; William D Leslie
Journal:  CMAJ       Date:  2010-10-12       Impact factor: 8.262

Review 3.  Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research.

Authors:  Robert A Adler; Ghada El-Hajj Fuleihan; Douglas C Bauer; Pauline M Camacho; Bart L Clarke; Gregory A Clines; Juliet E Compston; Matthew T Drake; Beatrice J Edwards; Murray J Favus; Susan L Greenspan; Ross McKinney; Robert J Pignolo; Deborah E Sellmeyer
Journal:  J Bone Miner Res       Date:  2016-01       Impact factor: 6.741

4.  Pamidronate and osteoporosis prevention in liver transplant recipients.

Authors:  Pietra Pennisi; Andrea Trombetti; Emiliano Giostra; Gilles Mentha; René Rizzoli; Carmelo E Fiore
Journal:  Rheumatol Int       Date:  2006-08-31       Impact factor: 2.631

5.  [Insufficiency fractures in rheumatology. Case report and overview].

Authors:  R Dreher; F Buttgereit; W Demary; B Görtz; G Hein; P Kern; A Schulz
Journal:  Z Rheumatol       Date:  2006-09       Impact factor: 1.372

6.  Ileum resection is the most predictive factor for osteoporosis in patients with Crohn's disease.

Authors:  R A van Hogezand; D Bänffer; A H Zwinderman; E V McCloskey; G Griffioen; N A T Hamdy
Journal:  Osteoporos Int       Date:  2006-01-04       Impact factor: 4.507

Review 7.  [Glucocorticoid induced osteoporosis].

Authors:  U Lange; U Müller-Ladner
Journal:  Z Rheumatol       Date:  2007-03       Impact factor: 1.372

8.  Absolute fracture risk.

Authors:  Chad L Deal
Journal:  Curr Rheumatol Rep       Date:  2007-04       Impact factor: 4.592

9.  A comparison of prediction models for fractures in older women: is more better?

Authors:  Kristine E Ensrud; Li-Yung Lui; Brent C Taylor; John T Schousboe; Meghan G Donaldson; Howard A Fink; Jane A Cauley; Teresa A Hillier; Warren S Browner; Steven R Cummings
Journal:  Arch Intern Med       Date:  2009-12-14

Review 10.  Bone health and prostate cancer.

Authors:  P J Saylor; M R Smith
Journal:  Prostate Cancer Prostatic Dis       Date:  2009-11-10       Impact factor: 5.554

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.